Sputum neutrophil elastase in bronchiectasis: a Southern European cohort study

TY - JOUR

T1 - Sputum neutrophil elastase in bronchiectasis

T2 - a Southern European cohort study

AU - Gramegna, Andrea

AU - Aliberti, Stefano

AU - Sibila, Oriol

AU - Di Francesco, Carlotta

AU - Sotgiu, Giovanni

AU - Perea, Lidia

AU - Terranova, Leonardo

AU - Oriano, Martina

AU - Pilocane, Tommaso

AU - Saderi, Laura

AU - Chalmers, James D.

AU - Marchisio, Paola

AU - Blasi, Francesco

PY - 2020/6/25

Y1 - 2020/6/25

N2 - Bronchiectasis is a chronic respiratory disease with neutrophilic airway inflammation playing a prominent role in its pathophysiology [1]. The inflammatory process depends on the release of neutrophil elastase (NE) and subsequent formation of neutrophil extracellular traps to facilitate the neutralisation of pathogens. An excessive release of NE can lead to several damaging lung effects, including mucus gland stimulation, increase in sputum production, impairment in ciliary beat frequency, and extracellular matrix and airway epithelia destruction. The activity of NE (aNE) has been previously evaluated in sputum samples of a Scottish cohort of bronchiectasis patients [2]. The authors demonstrated that increased levels of aNE in sputum are associated with disease severity and poor clinical outcomes. This experience identified NE as one of the most promising biomarkers in bronchiectasis and, subsquently, a point-of-care assay for aNE was validated [3].

AB - Bronchiectasis is a chronic respiratory disease with neutrophilic airway inflammation playing a prominent role in its pathophysiology [1]. The inflammatory process depends on the release of neutrophil elastase (NE) and subsequent formation of neutrophil extracellular traps to facilitate the neutralisation of pathogens. An excessive release of NE can lead to several damaging lung effects, including mucus gland stimulation, increase in sputum production, impairment in ciliary beat frequency, and extracellular matrix and airway epithelia destruction. The activity of NE (aNE) has been previously evaluated in sputum samples of a Scottish cohort of bronchiectasis patients [2]. The authors demonstrated that increased levels of aNE in sputum are associated with disease severity and poor clinical outcomes. This experience identified NE as one of the most promising biomarkers in bronchiectasis and, subsquently, a point-of-care assay for aNE was validated [3].

UR - https://www.scopus.com/pages/publications/85097509584

U2 - 10.1183/13993003.01702-2020

DO - 10.1183/13993003.01702-2020

M3 - Article

C2 - 32586875

SN - 0903-1936

VL - 56

JO - European Respiratory Journal

JF - European Respiratory Journal

IS - 1

ER -